Vonoprazan
Brand names: Voquezna Dual Pak, Voquezna Triple Pak · Active ingredient: Vonoprazan Fumarate
In short: VOQUEZNA TRIPLE PAK or VOQUEZNA DUAL PAK are indicated for the treatment of Helicobacter pylori (H. pylori) infection in adults .
What is Vonoprazan used for?
VOQUEZNA TRIPLE PAK or VOQUEZNA DUAL PAK are indicated for the treatment of Helicobacter pylori (H. pylori) infection in adults .
To reduce the development of drug-resistant bacteria and maintain the effectiveness of VOQUEZNA TRIPLE PAK, VOQUEZNA DUAL PAK and other antibacterial drugs, VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Vonoprazan dosage
VOQUEZNA TRIPLE PAK is a co-packaged product containing vonoprazan tablets, amoxicillin capsules, and clarithromycin tablets each given twice daily (in the morning and evening, 12 hours apart) with or without food, for 14 days
. The recommended adult oral dosage of VOQUEZNA TRIPLE PAK is the following:
In the morning, take 20 mg of vonoprazan (one oval pale red tablet), 1,000 mg of amoxicillin (two yellow capsules), and 500 mg of clarithromycin (one oval white tablet)
In the evening, take 20 mg of vonoprazan (one oval pale red tablet), and 1,000 mg of amoxicillin (two yellow capsules), and 500 mg of clarithromycin (one oval white tablet)
VOQUEZNA DUAL PAK is a co-packaged product containing vonoprazan tablets and amoxicillin capsules given with or without food, for 14 days . The recommended adult oral dosage of VOQUEZNA DUAL PAK is the following:
In the morning, take 20 mg of vonoprazan (one oval pale red tablet) and 1,000 mg of amoxicillin (two yellow capsules)
Mid-day, take 1,000 mg of amoxicillin (two yellow capsules)
In the evening, take 20 mg of vonoprazan (one oval pale red tablet) and 1,000 mg of amoxicillin (two yellow capsules)
The recommended dosage of VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK in adult patients with renal impairment is described in Table 1 .
Estimated GFR | Recommended Dosage
VOQUEZNA TRIPLE PAK | VOQUEZNA DUAL PAK
30 mL/minute or greater | 20 mg vonoprazan twice daily 1,000 mg amoxicillin twice daily 500 mg clarithromycin twice daily | 20 mg vonoprazan twice daily 1,000 mg amoxicillin three times daily
Less than 30 mL/minute | Use is not recommended
The recommended dosage of VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK in adult patients with hepatic impairment is described in Table 2 .
Classification | Recommended Dosage
VOQUEZNA TRIPLE PAK | VOQUEZNA DUAL PAK
Child-Pugh Class A | 20 mg vonoprazan twice daily 1,000 mg amoxicillin twice daily 500 mg clarithromycin twice daily | 20 mg vonoprazan twice daily 1,000 mg amoxicillin three times daily
Child-Pugh Class B | Use is not recommended
Child-Pugh Class C | Use is not recommended
If a dose is missed, administer VOQUEZNA TRIPLE PAK or VOQUEZNA DUAL PAK as soon as possible, within 4 hours after the missed dose. If more than 4 hours have passed, skip the missed dose and administer the next dose on the regularly scheduled time. Patients should continue the normal dosing schedule until the medication is completed.
How to take Vonoprazan — instructions & advice from the label
Hypersensitivity Reactions
Patients should be aware that VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK can cause allergic reactions in some individuals. Advise the patient to call their healthcare provider immediately if they develop a new rash, urticaria, drug eruptions, swelling of the face, difficulty in breathing or other symptoms of allergic reactions .
Acute Tubulointerstitial Nephritis
Advise patients to call their healthcare provider if they experience signs and/or symptoms associated with acute tubulointerstitial nephritis .
Severe Cutaneous Adverse Reactions
Advise patients about the signs and symptoms of serious skin manifestations. Instruct patients to stop taking VOQUEZNA TRIPLE PAK or VOQUEZNA DUAL PAK immediately and promptly report the first signs or symptoms of skin rash, mucosal lesions, or any other sign of hypersensitivity .
Drug Interactions
Advise patients that VOQUEZNA TRIPLE PAK or the individual components of VOQUEZNA TRIPLE PAK may interact with some drugs; therefore, advise patients to report to their healthcare provider the use of any other medications including natural substitutes and nutritional supplements. …
Warnings & precautions
Do not take this medicine if: Hypersensitivity Reactions
VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK are contraindicated in patients with a known hypersensitivity to any component of VOQUEZNA TRIPLE PAK: vonoprazan, amoxicillin (or other β-lactam antibacterials, e.g., penicillins and cephalosporins), or clarithromycin (or other macrolide antibacterial drugs, e.g., erythromycin) or VOQUEZNA DUAL PAK: vonoprazan or amoxicillin (or other β-lactam antibacterials, e.g., penicillins and cephalosporins) .
Rilpivirine-containing Products
VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK are contraindicated with rilpivirine-containing products .
Serious Adverse Reactions/Risks Due to Drug Interactions
Because of the clarithromycin component, VOQUEZNA TRIPLE PAK is contraindicated with concomitant use of:
Pimozide: There have been postmarketing reports of drug interactions when clarithromycin is co-administered with pimozide, resulting in cardiac arrhythmias (QT prolongation, ventricular tachycardia, ventricular fibrillation, and torsades de pointes) most likely due to inhibition of metabolism of these drugs by clarithromycin. Fatalities have been reported .
Lipid-lowering Agents: Lomitapide, simvastatin, and lovastatin
Ergot Alkaloids: Ergotamine or dihydroergotamine
Colchicine in patients with renal or hepatic impairment
Lurasidone: Coadministration of clarithromycin and lurasidone may lead to an increase in lurasidone exposure and the potential for serious adverse reactions .
Cholestatic Jaundice/Hepatic Dysfunction
VOQUEZNA TRIPLE PAK is contraindicated in patients with a history of cholestatic jaundice or hepatic dysfunction associated with prior use of clarithromycin. …
Vonoprazan side effects
The following serious adverse reactions are described below and elsewhere in labeling:
Hypersensitivity Reactions
Drug-Induced Enterocolitis Syndrome (DIES)
Acute Tubulointerstitial Nephritis
Clostridioides difficile-Associated Diarrhea
QT Prolongation
Hepatotoxicity
Serious Adverse Reactions Due to Concomitant Use with Other Drugs
Exacerbation of Myasthenia Gravis
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Adverse Reactions with VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK
The safety of VOQUEZNA TRIPLE PAK was evaluated in 675 adult patients (aged 20 to 82 years) in clinical trials in the United States, Europe and Japan and VOQUEZNA DUAL PAK was evaluated in 348 adult patients (aged 20 to 80 years) in a clinical trial in the United States and Europe. All the patients were screened and found to be positive for H. pylori infection.
The safety of VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK was evaluated in a randomized, controlled, double-blind triple therapy/open-label dual therapy study conducted in the United States and Europe in treatment-naïve H. pylori-positive adult patients. …
Drug interactions
Collated drug interaction information for the individual components in VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK is summarized below. Drug interaction studies with VOQUEZNA TRIPLE PAK or VOQUEZNA DUAL PAK have not been conducted.
These recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy .
Clarithromycin (a component of VOQUEZNA TRIPLE PAK) is a strong CYP3A inhibitor. Concomitant use of VOQUEZNA TRIPLE PAK with a drug(s) primarily metabolized by CYP3A may cause elevations in CYP3A substrate drug's concentrations that could increase or prolong both therapeutic and adverse effects of the concomitant drug.
Strong or Moderate CYP3A Inducers
Clinical Effect | Vonoprazan and clarithromycin are CYP3A substrates. Strong or moderate CYP3A inducers may decrease exposure of vonoprazan and clarithromycin , which may reduce the effectiveness of VOQUEZNA TRIPLE PAK.
Prevention or Management | Avoid concomitant use with VOQUEZNA TRIPLE PAK.
Probenecid
Clinical Effect | Amoxicillin undergoes tubular secretion. …
About this medicine
VOQUEZNA TRIPLE PAK contains vonoprazan tablets, 20 mg, amoxicillin capsules, 500 mg, and clarithromycin tablets, 500 mg for oral administration. VOQUEZNA DUAL PAK contains vonoprazan tablets, 20 mg and amoxicillin capsules, 500 mg for oral administration.
Vonoprazan Tablets
Vonoprazan (as the fumarate), is a potassium-competitive acid blocker (PCAB). Chemically, it is 1H-pyrrole-3-methanamine, 5-(2-fluorophenyl)-N-methyl-1-(3-pyridinylsulfonyl)-, (2E)-2-butenedioate (1:1). Its empirical formula is C17H16FN3O2S∙C4H4O4 with a molecular weight of 461.5. Vonoprazan has the following structure:
Vonoprazan fumarate is white to nearly white crystals or crystalline powder which melts at 194.8°C. Vonoprazan fumarate is soluble in dimethyl sulfoxide; sparingly soluble in
N,N
–dimethylacetamide, slightly soluble in
N,N
-dimethylformamide, methanol, and water; very slightly soluble in ethanol (99.5); and practically insoluble in 2-propanol, acetone, 1-octanol, and acetonitrile. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 0cb2ee04-8581-46c8-a781-7be170ab5c86. Read the full official label on DailyMed.